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Abstract: Background The off-label use of ferumoxytol (FE), an intravenous iron preparation for iron
deficiency anemia, as a contrast agent for MRI is increasing; therefore, it is critical to understand its
pharmacokinetics. Purpose To evaluate the pharmacokinetics of FE in the abdomen and pelvis, as as-
sessed with quantitative 1.5- and 3.0-T MRI relaxometry. Materials and Methods R2*, an MRI technique
used to estimate tissue iron content in the abdomen and pelvis, was performed at 1.5 and 3.0 T in 12
healthy volunteers between April 2015 and January 2016. Volunteers were randomly assigned to receive
an FE dose of 2 mg per kilogram of body weight (FE2mg) or 4 mg/kg (FE4mg). MRI was repeated at
1.5 and 3.0 T for each volunteer at five time points: days 1, 2, 4, 7, and 30. A radiologist experienced in
MRI relaxometry measured R2* in organs of the mononuclear phagocyte system (MPS) (ie, liver, spleen,
and bone marrow), non-MPS anatomy (kidney, pancreas, and muscle), inguinal lymph nodes (LNs), and
blood pool. A paired Student t test was used to compare changes in tissue R2*. Results Volunteers (six
female; mean age, 44.3 years ± 12.2 [standard deviation]) received either FE2mg (n = 5) or FE4mg (n
= 6). Overall R2* trend analysis was temporally significant (P < .001). Time to peak R2* in the MPS
occurred on day 1 for FE2mg and between days 1 and 4 for FE4mg (P < .001 to P < .002). Time to
peak R2* in non-MPS anatomy, LNs, and blood pool occurred on day 1 for both doses (P < .001 to P
< .09). Except for the spleen (at 1.5 T) and liver, MPS R2* remained elevated through day 30 for both
doses (P = .02 to P = .03). Except for the kidney and pancreas, non-MPS, LN, and blood pool R2*
returned to baseline levels between days 2 and 4 at FE2mg (P = .06 to P = .49) and between days 4 and
7 at FE4mg (P = .06 to P = .63). There was no difference in R2* change between non-MPS and LN R2*
at any time (range, 1-71 sec−1 vs 0-50 sec−1; P = .06 to P = .97). Conclusion The pharmacokinetics
of ferumoxytol in lymph nodes are distinct from those in mononuclear phagocyte system (MPS) organs,
parallel non-MPS anatomy, and the blood pool. © RSNA, 2019 Online supplemental material is available
for this article.
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I
ron oxide nanoparticles, including ultrasmall superpara-
magnetic iron oxides (USPIOs), are gaining clinical 
interest as alternative MRI contrast agents. Similar to 
gadolinium-based contrast agents, USPIOs can be injected 
as a bolus, thereby allowing dynamic imaging of the aorta, 
mesenteric and renal arteries, and first-pass perfusion of 
the liver and kidneys (1). Because of slow migration (range, 
12–14 hours) across the capillary endothelium, USPIOs 
are also useful as blood pool imaging agents for MR venog-
raphy (2). Iron oxide nanoparticles, including USPIOs, 
are sequestered and cleared by the mononuclear phagocyte 
system (MPS) (3). While monocytes and macrophages of 
the MPS are in numerous tissues throughout the body, 
they are most abundant in the liver, spleen, and bone mar-
row, and to a lesser extent, the lymph nodes (LNs). As cells 
of the MPS accumulate USPIO, they progressively lose 
T2-weighted signal. Importantly, metastases, which lack 
macrophages, do not accumulate USPIO. Thus, hepatic 
metastases and LNs containing metastatic or micrometa-
static disease can be identified by the lack of signal loss on 
T2-weighted MRI scans (4,5).
Ferumoxytol (FE) is an intravenous Food and Drug 
Administration–approved USPIO used to treat iron de-
ficiency anemia in patients with chronic kidney disease 
(6). Because of favorable physical properties, FE is be-
ing used off-label as an MRI contrast agent where the 
safety profile (0.02%–1.3% rate of severe adverse events 
[hypersensitivity or hypotension]) is similar to that of 
ionic iodinated contrast agents (7,8). Unlike with gado-
linium-based contrast agents that have renal and/or bili-
ary excretion, the body has no active excretory pathway 
to dispose of excess iron from FE administration. Thus, 
it is critical to understand the pharmacokinetics of FE 
when it is used off-label, particularly when considering 
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Background: The off-label use of ferumoxytol (FE), an intravenous iron preparation for iron deficiency anemia, as a contrast agent 
for MRI is increasing; therefore, it is critical to understand its pharmacokinetics.
Purpose: To evaluate the pharmacokinetics of FE in the abdomen and pelvis, as assessed with quantitative 1.5- and 3.0-T MRI 
relaxometry.
Materials and Methods: R2*, an MRI technique used to estimate tissue iron content in the abdomen and pelvis, was performed at 1.5 
and 3.0 T in 12 healthy volunteers between April 2015 and January 2016. Volunteers were randomly assigned to receive an FE dose 
of 2 mg per kilogram of body weight (FE
2mg
) or 4 mg/kg (FE
4mg
). MRI was repeated at 1.5 and 3.0 T for each volunteer at five time 
points: days 1, 2, 4, 7, and 30. A radiologist experienced in MRI relaxometry measured R2* in organs of the mononuclear phago-
cyte system (MPS) (ie, liver, spleen, and bone marrow), non-MPS anatomy (kidney, pancreas, and muscle), inguinal lymph nodes 
(LNs), and blood pool. A paired Student t test was used to compare changes in tissue R2*.
Results: Volunteers (six female; mean age, 44.3 years 6 12.2 [standard deviation]) received either FE
2 mg
 (n = 5) or FE
4 mg
 (n = 6). 
Overall R2* trend analysis was temporally significant (P , .001). Time to peak R2* in the MPS occurred on day 1 for FE
2mg
 and 
between days 1 and 4 for FE
4mg
 (P , .001 to P , .002). Time to peak R2* in non-MPS anatomy, LNs, and blood pool occurred 
on day 1 for both doses (P , .001 to P , .09). Except for the spleen (at 1.5 T) and liver, MPS R2* remained elevated  
through day 30 for both doses (P = .02 to P = .03). Except for the kidney and pancreas, non-MPS, LN, and blood pool R2* re-
turned to baseline levels between days 2 and 4 at FE
2mg
 (P = .06 to P = .49) and between days 4 and 7 at FE
4mg
 (P = .06 to  
P = .63). There was no difference in R2* change between non-MPS and LN R2* at any time (range, 1–71 sec21 vs 0–50 sec21;  
P = .06 to P = .97).
Conclusion: The pharmacokinetics of ferumoxytol in lymph nodes are distinct from those in mononuclear phagocyte system (MPS) 
organs, parallel non-MPS anatomy, and the blood pool.
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repeat administration for cancer staging and restaging. To our 
knowledge, the optimal dose, time to peak tissue concentra-
tion, and clearance from the organs of the MPS are unknown 
to date. Thus, the purpose of our study was to evaluate the 
pharmacokinetics of FE in the abdomen and pelvis, as assessed 
with quantitative MRI relaxometry at 1.5 and 3.0 T. We hy-
pothesize that (a) the time to peak tissue concentration and 
clearance of FE for the mononuclear phagocyte system (MPS) 
and non-MPS will differ and (b) peak tissue concentration and 
clearance of FE from the inguinal LNs, non-MPS, and blood 
pool will be similar.
Materials and Methods
Study Volunteers
Our prospective randomized clinical trial was compliant 
with the Health Insurance Portability and Accountability Act 
(HIPAA) and was approved by our local institutional review 
board (IRB). Twelve healthy volunteers were recruited from a 
local IRB-approved HIPAA-compliant database. Volunteers 
younger than 18 years were excluded. Volunteers signed writ-
ten informed consent.
Study Protocol
The study consisted of six visits over 4 weeks for each volunteer 
from April 2015 to January 2016. Eleven volunteers were im-
aged with noncontrast MRI at 1.5 and 3.0 T at each visit.
At visit 1 (day 0), noncontrast 1.5- and 3.0-T MRI examina-
tions of the abdomen and pelvis were performed in all volunteers 
to establish baseline R2*; this is an MRI technique used to esti-
mate tissue iron content.
Volunteers were randomly assigned to receive a dose of 2 mg 
FE per kilogram of body weight (FE
2mg
) (0.035 mmol FE per 
kilogram, n = 6) or 4 mg FE per kilogram of body weight (FE
4mg
) 
(0.07 mmol FE per kilogram, n = 6). The FE (Feraheme; AMAG 
Pharmaceuticals, Waltham, Mass) doses in our study were cho-
sen based on guidelines and doses used in the literature (9,10).
Injection parameters followed International Society for Mag-
netic Resonance in Medicine guidelines (9). Doses were diluted 
to 60 mL (saline) and were administered intravenously via bo-
lus injection at a rate of 2 mL/sec (Spectris Solaris; MedRAD, 
Warrendale, Pa) and were followed by a 20-mL saline flush. 
Bolus injection was performed as part of a companion study 
evaluating first-pass MR angiography (1). Volunteers’ vital signs 
were recorded prior to, during, and 15 and 60 minutes after FE 
administration. Volunteers were evaluated for hypersensitivity 
reactions at discharge.
For visits 2, 3, 4, 5, and 6, volunteers returned on days 1, 2, 
4, 7, and 30 after FE administration for 1.5- and 3.0-T MRI of 
the abdomen and pelvis. The imaging interval was designed to 
explore peak R2* and clearance of FE from the blood pool and 
MPS organs compared with non-MPS anatomy and LNs. Fig-
ure 1 shows an overview of the study protocol.
MRI Protocol
MRI was performed at 1.5 T (HDxt; GE Healthcare, Wauke-
sha, Wis) and 3.0 T (MR750; GE Healthcare) using an eight-
channel phased-array body coil at 1.5 T (USA Instruments/
GE Healthcare, Waukesha, Wis) or a 32-channel phased-array 
body coil at 3.0 T (Neocoil, Pewaukee, Wis). The MRI proto-
col included quantitative R2* mapping based on a chemical 
shift–encoded multiecho three-dimensional spoiled gradient-
echo pulse sequence.
Imaging parameters for chemical shift–encoded 1.5-T MRI 
were as follows: In the abdomen, axial acquisition was performed 
(repetition time msec/echo time msec, 15.5/1.24; DTE = 1.72 
msec; six echoes per repetition time; 256 3 160 3 32 matrix; 
400 3 360 mm field of view; 8.0-mm section thickness for a 
true spatial resolution of 1.6 3 2.3 3 8.0 mm; 5° flip angle; 
receiver bandwidth, 662.5 kHz). In the pelvis, axial acquisition 
was performed (15.5/1.24, DTE = 1.72 msec; six echoes per rep-
etition time; 256 3 160 3 80 matrix; 400 3 360 mm field of 
view; 3.0-mm slice thickness; true spatial resolution, 1.6 3 2.3 
3 3.0 mm; 12° flip angle; 662.5 kHz receiver bandwidth).
Imaging parameters for chemical shift–encoded 3.0-T MRI 
were as follows: In the abdomen, axial acquisition was performed 
(8.0/1.24; DTE = 1.01 msec; six echoes were obtained by inter-
leaving two echo trains of three echoes over two repetition times; 
256 3 144 3 28 matrix, 400 3 360 mm field of view; 8-mm 
slice thickness for a true spatial resolution of 1.6 3 2.8 3 
8.0 mm; 4° flip angle; receiver bandwidth, 6125 kHz). In the 
pelvis, axial acquisition was performed (8.0/1.24; DTE, 1.01 
msec; six echoes were obtained by interleaving two echo trains 
of three echoes over two repetition times; matrix, 256 3 160 3 
80; 400 3 360 mm field of view; 3-mm slice thickness for a true 
spatial resolution of 1.6 3 2.8 3 3.0 mm; flip angle, 9°; receiver 
bandwidth, 6125 Hz).
R2* Measurements
The chemical shift–encoded MRI data were processed by using 
a confounder-corrected R2* mapping algorithm that corrects 
Abbreviations
FE = ferumoxytol, FE
2mg
 = 2 mg/kg FE dose, FE
4mg
 = 4 mg/kg FE dose, 
LN = lymph node, MPS = mononuclear phagocyte system, ROI = re-
gion of interest, USPIO = ultrasmall superparamagnetic iron oxide
Summary
The 30-day pharmacokinetics of ferumoxytol in organs of the mono-
nuclear phagocyte system are distinct from those in organs such as the 
kidney, pancreas, and muscle; the pharmacokinetics of ferumoxytol in 
inguinal lymph nodes mirror those of the blood pool.
Key Results
 n After infusion of ferumoxytol, liver and spleen R2* peaked on days 
1 and 2, respectively.
 n Liver and spleen R2* returned to baseline level by day 30 after 
infusion of 2 mg/kg ferumoxytol but remained elevated after infu-
sion of 4 mg/kg ferumoxytol.
 n Peak R2* of kidney, pancreas, muscle, inguinal lymph nodes, and 
blood pool occurred 1 day after administration of both 2mg/kg 
and 4mg/kg of ferumoxytol.
 n Similar to blood pool, clearance of ferumoxytol from kidney, 
pancreas, muscle and inguinal lymph nodes occurred on day 2 for 
2mg/kg and day 4 for 4mg/kg at both 1.5 T and 3.0 T.
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Results
Eleven volunteers completed the study protocol 
(six female; mean age, 44.3 years 6 12.2 [stan-
dard deviation]; mean body mass index, 29.1 6 
5.5). One male volunteer had elevated liver R2* 
at baseline and was therefore excluded from the 
analysis. Five volunteers received FE
2mg
, and six 
volunteers received FE
4mg
. All imaging examina-
tions except one (day 2, FE
4mg
) were completed 
successfully. The overall R2* trend analysis was 
temporally significant (P , .001). No adverse 
events were observed.
Figure 2 shows quantitative R2* maps in the ab-





 at 1.5 T. Figure 3 shows quan-





 at 1.5 T. The phar-
macokinetics of FE can be observed qualitatively 
over the 30-day period for the MPS compared with 
inguinal LNs.
Inguinal Lymph Node R2*
Figures 4–6 compare LN R2* with MPS organ, 
non-MPS anatomy, and blood pool R2* before 








, LN R2* increased and peaked on day 1 at 1.5 T 
(27 sec21 vs 39 sec21, P = .01) and was similar to baseline R2* by 
day 2 (28 sec 21, P = .09). LN R2* did not change at 3.0 T (P = 
.06 to P = .42).
For FE
4mg
, LN R2* increased and peaked on day 1 at 1.5 T 
(18 sec21 vs 91 sec21, P = .003) and 3.0 T (51 sec21 vs 16 sec21, 
P = .002). LN R2* was similar to that at baseline by day 4 at 1.5 
T (30 sec21, P = .07) and by day 7 at 3.0 T (52 sec21, P = .24).
For FE
2mg
, there was no significant difference in change 
of R2* between LN and non-MPS anatomy (P = .1 for P = 
0.97). The median R2* change in LN ranged from 1 to 15 
sec21 at 1.5 T and from 1 to 11 sec21 at 3.0 T, while the me-
dian R2* change in non-MPS anatomy ranged from 0 to 14 
sec21 at 1.5 and 3.0 T.
For FE
4mg
, there was also no significant difference in change 
of R2* between LN and non-MPS anatomy (P = .06 to P = .76). 
The median R2* change in LN ranged from 1 to 71 sec21 at 1.5 
T and from 3 to 67 sec21 at 3.0 T, while the median R2* change 
in non-MPS anatomy ranged from 0 to 50 sec21 at 1.5 T and 
from 0 to 46 sec21 at 3.0 T.
R2* and change of R2* between LN and non-MPS anatomy 
at baseline and across visits is summarized in Table 1 for 1.5-T 




, R2* increased in the MPS organs (liver, spleen, and 
bone marrow, respectively) on day 1 at both 1.5 T (27 sec21 vs 
126 sec21, 9 sec21 vs 214 sec21, and 57 sec21 vs 231 sec21; P , 
.001) and 3.0 T (41 sec21 vs 148 sec21, 17 sec21 vs 230 sec21, 
and 138 sec21 vs 321 sec21; P , .001) and continued through 
day 7 (1.5 T: 45, 45, and 111 sec21; 3.0 T: 61, 62, and 199 
for the effects of fat and noise floor (11,12). R2* was measured 
by drawing two elliptical regions of interest (ROIs) on the liver 
(right and left lobes), spleen, kidney (cortex and medulla), in-
ferior vena cava, and lumbar (L2) and thoracic (T12) vertebral 
bodies (marrow), and one ROI on the pancreas, aorta, erector 
spinae muscle, and right and left inguinal lymph nodes. ROIs 
were drawn as large as possible to fit within the parenchyma 
of the specified organ, avoiding structures (eg, large blood ves-
sels, bile ducts) and obvious image artifacts. ROIs were placed 
independently by a board-certified radiologist (T.S., 9 years of 
experience in abdomen and pelvis MRI).
Statistical Analysis
R2* values were quantified at each visit for each dose at 1.5 and 
3.0 T. For anatomy with more than one ROI, measurements 
were averaged at each time point for each volunteer.
Linear trend analysis for all R2* measurements as a function 
of time was performed. MPS organs (liver, spleen, and bone 
marrow), non-MPS anatomy (kidney, pancreas, and muscle), 
and blood pool (aorta and inferior vena cava) were stratified. 
ROI measurements were averaged for blood pool and for each 
system at each time point for each volunteer. These stratified av-
erages were used for subsequent analysis. Median and interquar-
tile range are presented as summary statistics.
A paired Student t test was used to (a) evaluate change in 
organ, anatomy, and LN R2* from baseline, defined as contrast 
material–enhanced R2* minus noncontrast R2* and (b) com-
pare LN R2* with non-MPS anatomy R2*.
Statistical tests were two sided, and 5% (P , .05) was set 
as the level of significance. Statistical analysis was performed 
with open-source software (R, version 3.3.1; R Foundation, 
Vienna, Austria).
Figure 1: Study protocol diagram.
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sec21; P , .01). Similarly, after injection of 
FE
4mg
, R2* increased in the MPS organs on 
day 1 at both 1.5 T (44 sec21 vs 293 sec21, 
22 sec21 vs 360 sec21, and 80 sec21 vs 337 
sec21; P , .001) and 3.0 T (81 sec21 vs 319 
sec21, 37 sec21 vs 416 sec21, and 218 sec21 
vs 406 sec21; P , .001) and continued 
through day 30 (1.5 T: 100, 67, and 140 
sec21; 3.0 T: 153, 101, and 352 sec21; P , 
.02).
Time to peak R2* in the liver, spleen, and 
bone marrow occurred on day 1 for FE
2mg
 at 
1.5 and 3.0 T. However, time to peak R2* 
varied by organ and field strength for FE
4mg
. 
Liver R2* peaked on day 1 at both 1.5 and 
3.0 T, while spleen R2* peaked on day 2. 
Bone marrow R2* peaked on day 2 at 1.5 T 
and on day 4 at 3.0 T.
On day 30 for FE
2mg
, liver R2* was similar 
to baseline R2* at 1.5 T (30 sec21, P = .1) 
and 3.0 T (41 sec21, P = .76). Spleen R2* was 
similar to baseline R2* at 1.5 T (15 sec21, P = 
.13) but remained higher than baseline R2* 
at 3.0 T (22 sec21, P = .02). Bone marrow 
R2* remained higher than baseline R2* at 
both field strengths (1.5 T: 86 sec21, P = .02; 
3.0 T: 168 sec21, P = .03).
On day 30 for FE
4mg
, liver, spleen, and 
bone marrow R2* remained higher than 
baseline R2* at both field strengths (1.5 T: 
100, 67, and 140 sec21, respectively; 3.0 T: 
153, 101, and 352 sec21, respectively; P , 
.04). R2* of MPS organs at baseline and 





, R2* increased and peaked in the 
blood pool, kidney, and pancreas on day 1 
(5 sec21 vs 28 sec21, 13 sec21 vs 31 sec21, 19 
sec21 vs 35 sec21, respectively; P , .01). On 
day 2, only the R2* of blood pool at 1.5 T 
remained higher than that at baseline (12 
sec21, P = .02). By day 4, the R2* of blood 
pool at 1.5 T was similar to that at baseline 
(8 sec21, P = .13). Muscle did not demon-
strate a change in R2*.
Figure 2: R2* maps of the abdomen in a volunteer 
who received 2 mg/kg ferumoxytol (FE) (left) and a 
volunteer who received 4 mg/kg FE (right) show biodis-
tribution and clearance of FE in mononuclear phagocyte 
system organs (liver, spleen, and bone marrow) at 1.5-T 
MRI at baseline (BL) and across visits (days 1, 2, 4, 7, 
and 30). Window level was set to 220 sec21, and win-
dow width was set to 440 sec21 for all images.
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Figure 3: R2* maps of the pelvis in a volunteer who received 2 mg/kg ferumoxytol (FE) (left) and a volunteer who received 4 
mg/kg FE (right) show the biodistribution and clearance of FE in inguinal lymph nodes (arrows) at 1.5-T MRI at baseline (BL) and 
across visits (days 1, 2, 4, 7, and 30). Window level was set to 220 sec21, and window width was set to 440 sec21 for all images.
Wells et al
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Figure 5: Graphs show pharmacokinetics of ferumoxytol (FE) in the mononuclear phagocyte organs (liver, spleen, and bone marrow), blood pool (aorta and inferior 
vena cava), and inguinal lymph nodes across visits (days 0, 1, 2, 4, 7, and 30). Left: Pharmacokinetics of 2 mg/kg FE at 1.5- (top) and 3.0-T (bottom) MRI. Right: Pharma-
cokinetics of 4 mg/kg FE at 1.5- (top) and 3.0-T (bottom) MRI.
Figure 4: Graphs show pharmacokinetics of ferumoxytol (FE) in the mononuclear phagocyte system (MPS) organs (liver, spleen, and bone marrow), non-MPS anatomy 
(kidney, pancreas, and muscle), blood pool (aorta and inferior vena cava), and inguinal lymph nodes across visits (days 0, 1, 2, 4, 7, and 30). Left: Pharmacokinetics of 2 
mg/kg FE at 1.5- (top) and 3.0-T (bottom) MRI. Right: Pharmacokinetics of 4 mg/kg of FE at 1.5- (top) and 3.0-T (bottom) MRI.
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sec21, P = .04) and the kidney at 1.5 T (12 sec21 vs 19 sec21, 
P = .02), were similar to those at baseline. R2* of the pan-
creas and kidney were similar to baseline values by day 7. 
The R2* values of blood pool and non-MPS anatomy at 




, R2* of blood pool and non-MPS anatomy, 
including muscle, increased and peaked on day 1 (5 sec21 vs 
87 sec21 [blood pool], 12 sec21 vs 83 sec21 [kidney], 23 sec21 
vs 67 sec21 [pancreas], and 32 sec21 vs 44 sec21 [muscle]; P 
, .001). By day 4, R2* of the blood pool and non-MPS 
anatomy, except for the pancreas at 3.0 T (25 sec21 vs 40 
Table 1: Inguinal LN and Non-MPS Anatomy R2* Values at 1.5-T MRI at Baseline and across Visits after Intravenous Administra-
tion of Ferumoxytol
Time Point LN R2* Non-MPS R2* P Value LN R2* Change Non-MPS R2* Change P Value
Ferumoxytol 2 mg/kg at 1.5-T MRI Relaxometry
Baseline 21 (17–24) 17 (16–18) .18 … … …
Day 1 39 (37–41) 33 (30–33) .003 15 (13–24) 14 (13–17) .11
Day 2 29 (28–29) 21 (21–22) .003 8 (5–11) 3 (3–6) .23
Day 4 25 (20–28) 17 (17–18) .37 2 (1–7) 1 (0–2) .96
Day 7 19 (18–25) 17 (16–18) .36 1 (0–5) 0 (0–1) .97
Day 30 22 (21–25) 18 (16–19) .08 3 (0–5) 1 (0–1) .59
Ferumoxytol 4 mg/kg at 1.5-T MRI Relaxometry
Baseline 18 (17–20) 18 (17–19) .94 … … …
Day 1 91 (63–111) 68 (66–91) .45 71 (47–93) 50 (47–72) .45
Day 2 41 (40–78) 36 (35–39) .5 26 (20–60) 19 (18–19) .5
Day 4 30 (23–48) 23 (20–27) .11 13 (4–30) 3 (2–8) .12
Day 7 23 (20–33) 21 (21–24) .21 2 (2–16) 4 (2–6) .24
Day 30 21 (19–25) 17 (16–19) .08 1 (0–8) 0 (0–1) .13
Note.—Data are the median, and data in parentheses are the interquartile range. LN = inguinal lymph node, MPS = mononuclear phago-
cyte system.
Figure 6: Graphs show pharmacokinetics of ferumoxytol (FE) in the non–mononuclear phagocyte system anatomy (kidney, pancreas, and erector spinae muscle), 
blood pool (aorta and inferior vena cava), and inguinal lymph nodes across visits (days 0, 1, 2, 4, 7, and 30). Left: Pharmacokinetics of 2 mg/kg FE at 1.5- (top) and 3.0-T 
(bottom) MRI. Right: Pharmacokinetics of 4 mg/kg FE at 1.5- (top) and 3.0-T (bottom) MRI.
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Table 2: Inguinal Lymph Node and Non–Mononuclear Phagocyte System Anatomy R2* Values at 3.0-T MRI at Baseline and 
across Visits after Intravenous Administration of Ferumoxytol
Time Point LN R2* Non-MPS R2* P Value LN R2* Change Non-MPS R2* Change P Value
Ferumoxytol 2 mg/kg at 3.0-T MRI Relaxometry
Baseline 54 (52–60) 25 (22–25) ,.001 … … …
Day 1 67 (63–68) 38 (38–40) .002 11 (7–14) 14 (13–15) .46
Day 2 62 (62–74) 27 (24–30) ,.001 8 (6–9) 3 (2–4) .1
Day 4 57 (53–63) 24 (24–26) ,.001 1 (0–4) 0 (0–1) .68
Day 7 60 (55–64) 25 (28–29) ,.001 4 (3–4) 0 (0–1) .58
Day 30 60 (55–64) 24 (22–30) ,.001 3 (0–7) 0 (0–1) .44
Ferumoxytol 4 mg/kg at 3.0-T MRI Relaxometry
Baseline 51 (49–53) 22 (21–25) ,.001 … … …
Day 1 116 (94–129) 69 (68–95) .04 67 (42–81) 46 (43–74) .76
Day 2 76 (74–94) 42 (37–47) .01 23 (17–53) 21 (15–21) .4
Day 4 63 (61–75) 32 (29–35) .001 17 (8–27) 10 (5–11) .19
Day 7 52 (49–68) 25 (24–26) .002 3 (0–21) 2 (0–4) .39
Day 30 56 (54–59) 23 (22–23) ,.001 7 (3–8) 0 (0–0) .06
Note.—Data are the median, and data in parentheses are the interquartile range. LN = inguinal lymph node, MPS = mononuclear phago-
cyte system.
Discussion
Ferumoxytol (FE), an ultrasmall superparamagnetic iron oxide 
(USPIO) used to treat iron deficiency anemia in the setting of 
chronic kidney disease, is being increasingly used off-label as a 
contrast agent for MRI. Because the body has no active excre-
tory pathway to dispose of excess iron, it is critical to under-
stand the pharmacokinetics of FE. We evaluated the pharma-




, in the abdomen 
and pelvis with 1.5- and 3.0-T MRI relaxometry. As expected, 
the pharmacokinetics of FE in the mononuclear phagocyte 
system (MPS), which includes the liver, spleen, and bone 
marrow, are distinct from the pharmacokinetics of FE in the 
blood pool and non-MPS anatomy, including the kidney, 
pancreas, and muscle. MPS R2* remained elevated through 
day 30 for both doses (except for the liver and spleen at 1.5 T 
and with FE
2mg
) while non-MPS anatomy returned to base-
line by day 2 with FE
2mg
 (except blood pool) and by day 4 
with FE4
mg
 (except pancreas and muscle). Peak R2* of MPS 
organs was organ specific and dose dependent. R2* peaked 
in the liver, spleen, and bone marrow on day 1 at 1.5 and 




, R2* peaked in the liver on day 
1 and in the spleen on day 2 (at both field strengths), while 
bone marrow R2* peaked on day 2 at 1.5 T and on day 4 
at 3.0 T. The pharmacokinetics of FE in the inguinal lymph 
nodes paralleled blood pool and non-MPS anatomy. Similar 
to blood pool and non-MPS organ R2*, inguinal lymph node 
R2* peaked on day 1 and returned to the baseline level on day 
2 for FE
2mg
 and on days 4 (1.5 T) and 7 (3.0 T) for FE
4mg
.
The premise of using USPIO to detect metastatic dis-
ease depends on prolonged uptake in macrophages in lymph 
nodes and organs of the MPS. Unlike MPS organs, ingui-
nal lymph nodes do not demonstrate prolonged uptake of 
FE. Therefore, both normal lymph nodes and lymph nodes 
harboring metastatic disease would appear similar with 
MRI relaxometry. Our results support a recent phase I MR 
lymphography dosing study of 15 patients with prostate 
cancer (13). Turkbey et al (13) found that inguinal lymph 
node signal loss was heterogeneous and could result in 
false-positive diagnosis with 4, 6, or 7.5 mg/kg doses when 
imaged at 3.0 T 1 day after FE administration. In 2008, 
the European Medicines Agency, which is the European 
equivalent of the Food and Drug Administration, declined 
to approve the use of ferumoxtran 10 (Sinerem; Guerbet, 
Villepinte, France), a USPIO with a similar particle size as 
FE (mean diameter, 30 nm), for MR lymphography (14). 
They cited, among other studies, an unpublished random-
ized multicenter open-label trial that enrolled 271 patients 
with pelvic cancer (prostate, bladder, uterine, or cervix can-
cer) who underwent MRI and MR lymphography (dose, 2.6 
mg/kg) prior to lymphadenectomy. They found that MR 
lymphography lacked sensitivity, failed noninferiority for 
specificity, and demonstrated a lack of consistency among 
the three study radiologists. While the European Medicines 
Agency cited an increase in sensitivity, they concluded that a 
reduction in specificity might confound the potential thera-
peutic benefit for MR lymphography.
Our study adds to the growing body of literature demonstrat-
ing the excellent safety profile of intravenous FE when used with 
MRI. Similar to other recent MRI and MR lymphography stud-
ies (13,15–17), there were no serious adverse events in our study. 
Large cohort studies in patients with iron deficiency anemia 
from chronic kidney disease (n = 9820) found that the rate of 
serious adverse events (range, 0%–1%) and anaphylaxis (0.03%) 
was similar to those of ionic iodinated contrast agents (18–22). 
Importantly, the rate of serious adverse events may be even lower 
in imaging studies where the FE dose is, in general, substantially 
lower than the therapeutic doses (9). By diluting FE and reduc-
ing the rate of intravenous administration over 15 minutes, as 
recommended by the Food and Drug Administration, one may 
further mitigate the risk of serious adverse events.
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Our study had several limitations. Our study design 
with two doses and imaging at both 1.5 and 3.0 T are study 
strengths, but this created two relatively small groups. As a 
result, our study was underpowered to detect small differ-
ences in R2*, which likely explains the discrepancy in time 
to organ-specific peak R2* between field strengths. On the 
basis of the calculated residual errors, the between-group 
mean difference in R2* would need to be at least 40.1 sec21 
for 80% power. Because our study was performed in healthy 
volunteers, we used non-MPS tissues as a tumor surrogate. 
Similar to metastases, non-MPS tissues do not contain tis-
sue macrophages and do not accumulate USPIO. Therefore, 
we believe that the pharmacokinetics of FE in non-MPS tis-
sues should approximate metastases where perfusion is the 
primary source of signal change.
In conclusion, we found that peak R2* and maximum sig-
nal change in tissues of the mononuclear phagocyte system 
(MPS) are organ specific and dose dependent. At higher feru-
moxytol (FE) doses, biodistribution is constant but clearance 
is prolonged, with bone marrow likely representing the dose-
limiting organ. The pharmacokinetics of FE in inguinal lymph 
nodes closely parallel blood pool and non-MPS anatomy. 
Therefore, FE likely has little utility in detecting metastatic dis-
ease to these lymph nodes.
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